{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:49:00Z","timestamp":1767340140450,"version":"3.27.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,16]]},"DOI":"10.7759\/cureus.71655","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T23:23:23Z","timestamp":1729121003000},"source":"Crossref","is-referenced-by-count":1,"title":["A Case of Progressive Multifocal Leukoencephalopathy Caused by Epcoritamab"],"prefix":"10.7759","author":[{"given":"Chifumi","family":"Iseki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Nakamichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Toubai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section","volume":"80","author":"Berger JR","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB, et al.. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013, 80:1430-8. 10.1212\/WNL.0b013e31828c2fa1","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton KM","year":"2024","unstructured":"Linton KM, Vitolo U, Jurczak W, et al.. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024, 11:e593-605. 10.1016\/S2352-3026(24)00166-2","journal-title":"Lancet Haematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont C","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H, et al.. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol. 2023, 41:2238-47. 10.1200\/JCO.22.01725","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005529","article-title":"Progressive multifocal leukoencephalopathy after fingolimod treatment","volume":"90","author":"Berger JR","year":"2018","unstructured":"Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, Dong VM, Merschhemke M. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. 2018, 90:e1815-21. 10.1212\/WNL.0000000000005529","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-12-121","article-title":"Characteristics of progressive multifocal leukoencephalopathy clarified through internet-assisted laboratory surveillance in Japan","volume":"12","author":"Nakamichi K","year":"2012","unstructured":"Nakamichi K, Mizusawa H, Yamada M, et al.. Characteristics of progressive multifocal leukoencephalopathy clarified through internet-assisted laboratory surveillance in Japan. BMC Neurol. 2012, 12:121. 10.1186\/1471-2377-12-121","journal-title":"BMC Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1476-2","article-title":"Improving detection of JC virus by ultrafiltration of cerebrospinal fluid before polymerase chain reaction for the diagnosis of progressive multifocal leukoencephalopathy","volume":"19","author":"Nakamichi K","year":"2019","unstructured":"Nakamichi K, Kawamoto M, Ishii J, Saijo M. Improving detection of JC virus by ultrafiltration of cerebrospinal fluid before polymerase chain reaction for the diagnosis of progressive multifocal leukoencephalopathy. BMC Neurol. 2019, 19:252. 10.1186\/s12883-019-1476-2","journal-title":"BMC Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts PJ","year":"2020","unstructured":"Engelberts PJ, Hiemstra IH, de Jong B, et al.. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020, 52:102625. 10.1016\/j.ebiom.2019.102625","journal-title":"EBioMedicine"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120459","article-title":"Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: a review","volume":"443","author":"Sharma K","year":"2022","unstructured":"Sharma K, Tolaymat S, Yu H, et al.. Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: a review. J Neurol Sci. 2022, 443:120459. 10.1016\/j.jns.2022.120459","journal-title":"J Neurol Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577721","article-title":"Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: a systematic review and meta-analysis","volume":"360","author":"Sriwastava S","year":"2021","unstructured":"Sriwastava S, Kataria S, Srivastava S, et al.. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: a systematic review and meta-analysis. J Neuroimmunol. 2021, 360:577721. 10.1016\/j.jneuroim.2021.577721","journal-title":"J Neuroimmunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1086\/595299","article-title":"Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study","volume":"199","author":"Engsig FN","year":"2009","unstructured":"Engsig FN, Hansen AB, Omland LH, et al.. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis. 2009, 199:77-83. 10.1086\/595299","journal-title":"J Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp256","article-title":"Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials","volume":"101","author":"Tuccori M","year":"2009","unstructured":"Tuccori M, Focosi D, Blandizzi C, Del Tacca M, Petrini M. Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2009, 101:1288-9. 10.1093\/jnci\/djp256","journal-title":"J Natl Cancer Inst"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0098","article-title":"Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy","volume":"15","author":"Tuccori M","year":"2010","unstructured":"Tuccori M, Focosi D, Blandizzi C, et al.. Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist. 2010, 15:1214-9. 10.1634\/theoncologist.2010-0098","journal-title":"Oncologist"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson KR","year":"2009","unstructured":"Carson KR, Evens AM, Richey EA, et al.. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009, 113:4834-40. 10.1182\/blood-2008-10-186999","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr418","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials","volume":"103","author":"Vidal L","year":"2011","unstructured":"Vidal L, Gafter-Gvili A, Salles G, et al.. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2011, 103:1799-806. 10.1093\/jnci\/djr418","journal-title":"J Natl Cancer Inst"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12840","article-title":"The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy","volume":"136","author":"Reuwer AQ","year":"2017","unstructured":"Reuwer AQ, Heron M, van der Dussen D, Schneider-Hohendorf T, Murk JL. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy. Acta Neurol Scand. 2017, 136:37-44. 10.1111\/ane.12840","journal-title":"Acta Neurol Scand"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik L","year":"2010","unstructured":"Gorelik L, Lerner M, Bixler S, et al.. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010, 68:295-303. 10.1002\/ana.22128","journal-title":"Ann Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-311100","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan C","year":"2016","unstructured":"McGuigan C, Craner M, Guadagno J, et al.. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2016, 87:117-25. 10.1136\/jnnp-2015-311100","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/220876-a-case-of-progressive-multifocal-leukoencephalopathy-caused-by-epcoritamab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T23:23:24Z","timestamp":1729121004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/220876-a-case-of-progressive-multifocal-leukoencephalopathy-caused-by-epcoritamab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.71655","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,16]]}}}